Nayef Abouzaki, MD
Interventional Cardiology · Richmond, VANPI 1164742359
Payments from drug & device makers
What this record shows
This record is dominated by food and beverage: $7,057 of the $8,129 with a category attached, or 86.8%. It is spread thinly across 40 manufacturers, the largest accounting for just 19.6% — the pattern of someone who eats at a lot of different presentations.
Across 232 payments — averaging $35.04 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Abbott$2K
- Boston Scientific$720
- Medtronic$706
- Shockwave Medical, Inc$458
- Abiomed$431
- Novartis$367
- plus $4K from 34 others
Across 31 payments — averaging $7787.90 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- M.a. Med Alliance S.A.$191K
- Cleerly, Inc.$47K
- Medalliance LLC$3K
What the payments were for
- Travel & lodging$1,00112%
- Food & beverage$7,05787%
- Education$721%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Abbott | 13 | $1,597 |
| Boston Scientific | 19 | $720 |
| Medtronic(2 entities) | 10 | $706 |
| Shockwave Medical, Inc | 7 | $458 |
| Abiomed | 9 | $431 |
| Novartis | 18 | $367 |
| Alnylam Pharmaceuticals Inc. | 20 | $358 |
| Bayer | 15 | $303 |
| Recor Medical Inc | 3 | $297 |
| Novo Nordisk | 13 | $275 |
| Merck | 14 | $238 |
| Johnson & Johnson | 7 | $235 |
| Pfizer | 11 | $191 |
| Teleflex LLC | 1 | $150 |
| W. L. Gore & Associates, Inc. | 1 | $148 |
| Cardiva Medical, Inc. | 6 | $147 |
| Cardiovascular Systems Inc. | 3 | $143 |
| AstraZeneca | 7 | $138 |
| Impulse Dynamics (USA) Inc. | 6 | $128 |
| E.r. Squibb & Sons, L.L.C. | 7 | $123 |
| Cordis US CORP. | 1 | $120 |
| Boehringer Ingelheim | 6 | $106 |
| Philips North America LLC | 3 | $104 |
| Amgen | 5 | $97 |
| Penumbra, Inc. | 2 | $66 |
| Lilly USA, LLC | 3 | $54 |
| ZOLL Services LLC (a/k/a ZOLL Lifecor Corp) | 2 | $50 |
| Atricure, Inc. | 1 | $48 |
| Kestra Medical Technology Services, Inc. | 2 | $44 |
| Regeneron Healthcare Solutions, Inc. | 2 | $42 |
| Bridgebio Pharma, Inc. | 2 | $38 |
| Kiniksa Pharmaceuticals, Ltd. | 2 | $34 |
| Esperion Therapeutics, Inc. | 2 | $33 |
| Heartflow, Inc. | 1 | $23 |
| Lantheus Medical Imaging, Inc. | 1 | $23 |
| Sanofi-aventis U.S. LLC | 1 | $22 |
| Kiniksa Pharmaceuticals International, PLC | 1 | $21 |
| GE HealthCare | 3 | $20 |
| Scpharmaceuticals Inc. | 1 | $16 |
| GSK | 1 | $13 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$8,129 in reported general payments places this provider in the 65th percentile of 176 interventional cardiology providers in Virginia.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| JardianceEmpagliflozin | 371 | $421,398 |
| EntrestoSacubitril/Valsartan | 287 | $354,888 |
| EliquisApixaban | 213 | $249,278 |
| FarxigaDapagliflozin Propanediol | 228 | $208,206 |
| XareltoRivaroxaban | 106 | $112,681 |
| OzempicSemaglutide | 101 | $104,739 |
| Repatha SureclickEvolocumab | 57 | $48,044 |
| MounjaroTirzepatide | 17 | $24,751 |
| TrulicityDulaglutide | 20 | $21,160 |
| DapagliflozinDapagliflozin Propanediol | 15 | $6,742 |
| Spironolactone | 650 | $5,148 |
| Ezetimibe | 179 | $4,465 |
| Eplerenone | 76 | $4,355 |
| Atorvastatin Calcium | 431 | $4,214 |
| Metoprolol Succinate | 376 | $4,183 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Boehringer IngelheimJardiance | $106 | $421,398371 claims |
| NovartisEntresto | $367 | $354,888287 claims |
| PfizerEliquis | $191 | $249,278213 claims |
| AstraZenecaFarxiga | $138 | $208,206228 claims |
| Johnson & JohnsonXarelto | $235 | $112,681106 claims |
| Novo NordiskOzempic | $275 | $104,739101 claims |
| Lilly USA, LLCMounjaro, Trulicity | $54 | $45,91137 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 65th percentile of 176 interventional cardiology providers in Virginia.
Other interventional cardiology in Richmond
- Gansevoort DunningtonRichmond$440K
- Matthew ChungRichmond$75K
- Ashwani KumarRichmond$35K
- Brinder KandaRichmond$34K
- James GarnettRichmond$19K
- Barbara LawsonRichmond$17K
- John PosenauRichmond$11K
- Michael ArcareseRichmond$10K
- Sam DowRichmond$10K
- Deepak TalrejaVirginia Beach$1.5M
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.